Establishment Labs reports Q4 EPS (9c), consensus (22c)

Reports Q4 revenue $64.62M, consensus $64.12M. “Our growth and momentum from 2025 has continued into 2026 with strong demand from both surgeons and patients,” said Peter Caldini, CEO. “Preserve has been exceptionally well received in markets around the globe, creating market expansion in both dollar and procedure volumes. We have pioneered a new category of tissue-preserving and minimally invasive options which offer patients the benefits of minimal anesthesia and faster recovery. This is broadly resonating with a whole new group of consumers and driving meaningful growth for plastic surgery and Establishment Labs (ESTA).”